Two specialty pharma companies, which have licensed-in rights to a new formulation of the opioid, fentanyl, from Orexo AB in Sweden, said interim results from a Phase 3 study of the product were positive.
Pronova BioPharma ASA said it plans to use an alginate-based capsule technology in the future development of its lead product, Omacor/Lovaza, as well as other products in its pipeline in what appears to be a move to protect its patent position.
Pharming Group NV said that it plans to appeal against the European Medicines Agency’s negative opinion for Rhucin, its proposed treatment for patients with acute attacks of hereditary angioedema (HAE). The opinion was delivered on 13 December 2007 by the agency’s main scientific committee, the Committee for Medicinal Products for Human Use (CHMP).
ReNeuron Group Plc expects that its candidate stem cell treatment for stroke will be tested in man for the first time in 2008. This follows the UK-based company’s recent submission of an amended investigational new drug (IND) application to the US Food and Drug Administration.
The founders of Celtic Pharma, a specialised private equity firm, are launching two new funds to invest in products and companies that show promise of addressing unmet medical needs.
GlaxoSmithKline (GSK) has announced strategic alliances with biotechnology companies in Belgium and the US that will give it access to technology for developing new anti-infective and anti-cancer medicines.
MorphoSys AG of Germany and GeneFrontier Corporation of Japan are expanding their partnership arrangements to cover the commercialisation of therapeutic targets produced by Japanese research institutes and universities that make use of MorphoSys’s huge antibody library.
Cambridge Laboratories (Ireland) Ltd said that an advisory panel of the US Food & Drug Administration (FDA) has recommended approval of its treatment for chorea associated with Huntington’s disease, Xenazine (tetrabenazine).
Novartis AG has extended its three-year-old research collaboration with the German biotechnology company, MorphoSys AG, by 10 years in order to increase its involvement in developing therapeutic antibodies, which is MorphoSys’s specialty.
Evotec AG has completed the sale of its chemical development business, which includes an active pharmaceutical ingredient (API) facility in Oxford, UK, and a parenteral, fill-finish facility in Glasgow, UK, to Aptuit Inc. of the United States for a consideration of £31.5 million.